Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 20 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (4)
Early P 1 (2)
P 1 (3)
P 2 (2)

Trial Status

Completed6
Not Yet Recruiting4
Unknown4
Recruiting4
Withdrawn1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 6 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT07843459Phase 1Not Yet Recruiting

A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT07787182Phase 1Not Yet Recruiting

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787169Phase 1Not Yet Recruiting

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

NCT07589595Phase 2Recruiting

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

NCT07815132Not ApplicableCompletedPrimary

Fractional CO₂ Laser for Primary Cutaneous Amyloidosis

NCT07130565RecruitingPrimary

Pan-Amyloid PET/CT in Various Amyloid-Related Disease

NCT07232459RecruitingPrimary

[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis

NCT06725706RecruitingPrimary

Beta Amyloid PET/CT in Various Aβ-Related Disease

NCT05150353Not ApplicableCompletedPrimary

Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)

NCT05138848Early Phase 1Completed

Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease

NCT03431896Completed

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

NCT04270175Phase 2Active Not RecruitingPrimary

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT07105501Completed

Atrial Amyloid May Influence Outcomes in Patients Undergoing Surgical Aortic Valve Replacement

NCT06186167UnknownPrimary

Amyloidosis Incidence in High-Risk Cardiac Device Patients

NCT05200897Not ApplicableUnknown

Transdermal Trigeminal Electrical Neuromodulation on Mild Cognitive Impairment With Insomnia

NCT06048601Not ApplicableUnknownPrimary

18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis

NCT04984330Early Phase 1WithdrawnPrimary

Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

NCT03923920CompletedPrimary

Screening for Systemic Amyloidosis Via the Ligamentum Flavum

NCT04760171Not Yet RecruitingPrimary

Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis

NCT04027712Unknown

Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

Showing all 20 trials

Research Network

Activity Timeline